CBR | by CooperSurgical®

Newborn Stem Cell Quarterly Review: Q3 2023

Our featured stories this quarter shine a light on the profound importance of patient education. Awareness plays a pivotal role in empowering a wider range of patients to discover the potential benefits linked to preserving newborn stem cells.

One patient's hydrocephalus journey from diagnosis to cord blood infusion

During the five weeks between their daughter Lily's in utero diagnosis of hydrocephalus and her birth by C-section, a Virginia family began researching the best ways to navigate the challenges that lay ahead.†

It was during this process that they learned they were eligible for the CBR® Newborn Possibilities Program® and that Duke University's Expanded Access Protocol offered the possibility of cord blood infusions for children with hydrocephalus from family-banked cord blood.[1]

Lily was born via C-section at 37 weeks and spent her first 10 days in the NICU. At 7 weeks, she underwent successful shunt surgery which helped relieve cranial pressure on the optic nerve which causes the pupils to rest below the lower eyelids. Ongoing hurdles, such as vision impairment and motor delays, were addressed through various therapies.

At 14 months of age, Lily underwent a stem cell infusion using her own cord blood sample preserved by CBR. Lily's family noticed improvements in her condition soon after. Now, approaching her third birthday, she confidently walks without assistance and is described as an exceptionally bright and vivacious child.

Read Lily's story



Novel Australian study demonstrates adequate collection of cord blood in extremely preterm babies

Researchers at Monash Children's Hospital in Melbourne, Australia, have reached a significant milestone in the world's inaugural study on umbilical cord blood collection for extremely preterm infants. Supported by Cell Care™, CBR's sister company in Australia, an impressive 70% of the collections from participating patients had an adequate volume of cord blood for cryopreservation.[2]

Building on this research, the Monash Children's Hospital team is currently conducting an ongoing trial known as CORD-SAFE. This trial aims to evaluate the safety and feasibility of autologous umbilical cord blood infusions for babies born before 28 weeks of gestation.[3] The study results are anticipated to be published by the end of 2023.

Read article

Exclusive pricing for the OB/GYN and midwife community

CBR offers you and your staff significant savings on newborn stem cell preservation. Speak to your CBR rep or call Healthcare Provider Support at **1.888.588.0258**.

1. Kurtzberg, Joanne, "Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries," ClinicalTrials.gov, 2023, Sept. 5, https://clinicaltrials.gov/study/NCT03327467. 2. Zhou L, McDonald CA, Yawno T, Penny T, Miller SL, Jenkin G, Malhotra A. Feasibility of cord blood collection for autologous cell therapy applications in extremely preterm infants. Cytotherapy. 2023 May;25(5):458-462. doi: 10.1016/j.jcyt.2023.01.001. Epub 2023 Feb 4. PMID: 36740465. 3. Malhotra et al. (2020). Autologous Umbilical Cord Blood-Derived Cell Administration in Extreme Preterm Infants: protocol for a safety and feasibility study. Stem Cells Translational Medicine. May 11;10(5).

†This family's personal experiences are not necessarily representative of other's experiences and cannot predict outcomes for others. CBR cannot and does not guarantee specific results.

CBR | by CooperSurgical®

Newborn Stem Cell Quarterly Review: Q3 2023

Join the CBR® Healthcare Provider Network

The CBR Healthcare Provider Network (HPN) is a free service offered exclusively to the delivering healthcare professional community. This indispensable resource provides the specialized support and resources necessary to help you talk to your patients about potentially protecting their family's future health with newborn stem cell preservation. As a member, you'll receive:

- Payment for your services when you collect cord blood and/or cord tissue for CBR patients, per the HPN agreement
- Easy, no-cost newborn stem cell collection training
- Updates on the latest newborn stem cell news and clinical studies
- Exclusive print and digital patient education materials for your office
- Support from CBR representatives

Learn more

New handout facilitates patient conversations about newborn stem cell preservation

Perfect for a patient's 12-week checkup, CBR has a newly updated handout showing how cord blood and cord tissue preservation are transforming the fields of transplant and regenerative medicine.

This easy-to-share handout explains the benefits of newborn stem cell preservation in approachable terms for expectant parents. Get your copy today.

Download now

Best practices for cord blood collection

Based on 30-plus years' experience processing more than one million newborn stem cell samples,[1] we've found that following a few crucial steps can improve the quality of the collections. Download our Quality Collection Handout for a clear, step-by-step guide on newborn stem cell collection.

Download now

Connect with CBR®

Looking for more information to support your patients?

We've got you covered. Please visit **cordblood.com/providers** or call **1.888.588.0258** to speak with a representative today.

1. Internal data on file.

The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available.

Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord–derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.